Chiusura precedente | 4,7400 |
Aperto | 4,7500 |
Denaro | 4,6000 x 200 |
Lettera | 4,6600 x 100 |
Min-Max giorno | 4,5800 - 4,7500 |
Intervallo di 52 settimane | 1,1110 - 6,7200 |
Volume | |
Media Volume | 1.328.531 |
Capitalizzazione | 521,883M |
Beta (5 anni mensile) | 2,39 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,2000 |
Prossima data utili | 12 ago 2024 - 16 ago 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 8,60 |
VANCOUVER, Wash. and NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the speaker lineup for its inaugural R&D Day on Wednesday, October 4th, 2023. The program will begin at 9:00 a.m. Eastern Time and feature presentations from: Sean McClain, Founder & CEOZach Jonasson, Ph.D., Chief Financial Officer & Chief Business OfficerAndreas Busch, Ph.D., Chief Innovation OfficerAmaro Taylor-Weiner, Ph.D., Chief AI Office
VANCOUVER, Wash. and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will host its first R&D Day on Wednesday, October 4th, 2023 in New York City. The program will begin at 9:00 a.m. Eastern Time and feature presentations from members of Absci’s leadership team as well as guest speakers, followed by an interactive Q&A session. The program is expected to conclude at approximately 12:00 p.m. Eastern T
VANCOUVER, Wash. and NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. H.C. Wainwright 25th Annual Global Investment ConferenceFireside chat on Monday, September 11th at 2:00 p.m. Eastern Time Morgan Stanley 21st Annual Global Healthcare ConferenceFireside chat on Wednesday, September 13th at 4:55 p.m. Eastern Time 2023 Cantor Fitzge